Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation

Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation

Abstract Clinical responses with chimeric antigen receptor (CAR) T cells are encouraging, but primary resistance and relapse after therapy prevent durable remission in many patients with cancer, with apoptosis resistance in cancer cells that limits killing by CAR T cells being a potential cause. Her...

Full description

Saved in:
Bibliographic Details
Main Authors: Thomas Kimman, Marta Cuenca, Ralph G. Tieland, Dedeke Rockx-Brouwer, Jasmijn Janssen, Benjamin Motais, Anne Slomp, Corine Pleijte, Sabine Heijhuurs, Angelo D. Meringa, Wendy Boschloo, Douwe MT Bosma, Sanne Kroos, Vania lo Presti, Joost P. G. Sluijter, Stefan Nierkens, Niels Bovenschen, Jürgen Kuball, Alain van Mil, Monique C. Minnema, Zsolt Sebestyén, Victor Peperzak
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-59818-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-025-59818-8

Similar Items